logo
logo

Ferrer and Prilenia Sign Agreement for Pridopidine Co-Development and Commercialization

Apr 28, 20253 months ago

Contract Type

agreement

BarcelonaPharmaceuticalBiotechnologyHealth Care

Description

Ferrer, a pharmaceutical company with a focus on rare neurological diseases, has entered into a strategic co-development and license agreement with Prilenia Therapeutics B.V., a clinical-stage biotech company, for the development, manufacture, and commercialization of Pridopidine. Pridopidine, an orally administered sigma-1 receptor agonist, is a promising candidate for the treatment of Huntington’s Disease.

Company Information

Company

Ferrer

Location

Barcelona, Catalonia, Spain

About

Ferrer is an international pharmaceutical company that is certified as a B Corporation. It focuses on improving health and quality of life through the development of innovative medicines and healthcare solutions. With a commitment to sustainability, Ferrer emphasizes social and environmental responsibility in its operations.

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Related People